Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk launches new US insulin campaign

US IndyCar driver, diabetic and FlexPen user Charlie Kimball fronts activities

Novo-Nordish-IndyCar

Novo Nordisk has launched a campaign featuring IndyCar Series driver Charlie Kimball.

Agencies supporting the campaign include Tip Nunn, Chip Ganassi Racing and New York-based Marina Maher Communications, whose client case studies include Merck & Co and Pfizer. 

Diagnosed with diabetes during a routine visit to a GP while racing in Europe in 2007, Kimball is the first licensed driver with diabetes to race at the highest level of the series.

The campaign features a website www.RaceWithinsulin.com hosting a competition inviting entrants to build a 'pit crew' by enrolling two friends by email and be in with a chance of winning a VIP trip to the 2013 IndyCar finale and a Twitter feed. Campaign information booths will also be displayed at US racing venues.

A keen advocate of the notion that good management of diabetes is a team effort, Kimball says that it was working as a team that enables him to stay healthy on the track.

Kimball, who has a continuous blood sugar monitor said: ”It takes an entire crew to help me manage both my car and my diabetes, so we can compete at the highest levels”. “This programme is a great way for people to show support, especially for friends and family affected by diabetes, and encourage them to share my story.”

25th April 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics